Immuron (IMRN) Revenue (2016 - 2024)
Immuron's quarterly Revenue came in at -$2612125655.3 billion in Q4 2024, down 110890976120175.95% year-on-year from N/an in Q1 2024, and down 110890976120175.95% quarter-over-quarter from $2.4 million in Q4 2023.
Immuron has reported Revenue for 9 years, with the latest figure at -$2612125655.3 billion in Q4 2024.
- For the quarter ending Q4 2024, Revenue fell 110890976120175.95% year-over-year to -$2612125655.3 billion; the trailing twelve-month figure through Dec 2024 stood at -$2612125655.3 billion (down 154967425322.86% YoY), and the FY2025 full-year result was $4.7 million, up 46.88% from the prior year.
- Revenue for Q4 2024 stood at -$2612125655.3 billion, down from $2.4 million in the prior quarter.
- The five-year high for Revenue was $1.7 billion in Q4 2021, with the low at -$2612125655.3 billion in Q4 2024.
- Average Revenue over 5 years is -$435354275.6 billion, with a median of $333294.1 recorded in 2022.
- Year-over-year, Revenue surged 11334524.14% in 2021 and tumbled 110890976120175.95% in 2024.
- Tracing IMRN's Revenue over 5 years: stood at $14844.6 in 2020, then surged by 11334524.14% to $1.7 billion in 2021, then slumped by 99.97% to $583646.0 in 2022, then jumped by 303.6% to $2.4 million in 2023, then plunged by 110890976120175.95% to -$2612125655.3 billion in 2024.
- The last three Revenue figures came in at -$2612125655.3 billion (Q4 2024), $2.4 million (Q4 2023), and $82942.2 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2,612,125,655.29 Bn |
| Dec 31, 2023 | 2.36 Mn |
| Jun 30, 2023 | 82,942.19 |
| Dec 31, 2022 | 583,646.00 |
| Dec 31, 2021 | 1.68 Bn |
| Dec 31, 2020 | 14,844.55 |
| Dec 31, 2019 | 15,566.23 |
| Dec 31, 2018 | 978,233.00 |
| Dec 31, 2017 | 716,323.37 |
| Dec 31, 2016 | 530,121.20 |
| Jun 30, 2016 | 862,831.81 |